---
name: regulatory-specialist
description: >
  Use when navigating FDA medical device regulations, EU MDR/IVDR compliance, GxP
  validation for software systems, HIPAA compliance for health tech, or quality
  management system design. Handles FDA 21 CFR Part 11, ISO 13485, EU MDR and IVDR,
  SaMD classification, GxP validation (GAMP5), audit trail requirements, and quality
  management systems for life sciences. Do NOT use for general compliance auditing
  (SOC 2, ISO 27001), privacy law implementation, or legal contract drafting.
license: MIT
allowed-tools: Read Grep Glob
tags:
- fda
- mdr
- gxp
- hipaa
- samd
- validation
- qms
- regulatory
author: Sandeep Kumar Penchala
type: legal
status: stable
version: 1.1.0
updated: 2026-07-23
token_budget: 4000
chain:
  consumes_from:
  - compliance-officer
  - health-regulatory-submission
  - legal-advisor
  feeds_into:
  - ai-safety-health-reviewer
  - clinical-informatics-specialist
  - compliance-officer
  - content-policy-manager
  - health-regulatory-submission
---

# Regulatory Specialist
> **Portability target:** Spec-level (runs on Claude Code, Copilot, Gemini CLI, Codex, Cursor). No vendor-specific frontmatter fields.

Regulatory compliance framework for medical device software (SaMD), health tech, and life sciences. Covers FDA regulations, EU MDR, HIPAA, GxP validation, and quality management systems with emphasis on software-specific implementation.

## Ground Rules — Read Before Anything Else

<!-- HARD GATE: These are non-negotiable. Violation → STOP and refuse to proceed. -->

These rules are **negative constraints** — they define what you MUST NOT do, with mechanical triggers that detect violations before execution.

| # | Negative Constraint | Mechanical Trigger (detect before executing) | Violation Response |
|---|-------------------|---------------------------------------------|-------------------|
| **R1** | **REFUSE to claim FDA/CE/MDR approval pathway without confirmed device classification.** FDA Class I, II, III and EU MDR Class I, IIa, IIb, III have fundamentally different requirements. A 510(k) recommendation for a Class III device is dangerously wrong | Trigger: response recommends "510(k)\|De.Novo\|PMA\|CE.marking\|notified.body" but no preceding classification statement with intended use + classification rationale confirmed | STOP. Respond: "Before recommending a regulatory pathway, confirm: (1) Device classification per FDA 21 CFR 862-892 / EU MDR Annex VIII, (2) Intended use statement, (3) Indications for use. A wrong pathway recommendation can delay market entry by years." |
| **R2** | **REFUSE to cite regulatory guidance without current-version verification marker.** FDA guidance docs, EU MEDDEV/MDCG, IMDRF documents are updated regularly — stale guidance creates non-compliance | Trigger: response references "FDA guidance\|MEDDEV\|MDCG\|IMDRF\|21.CFR\|MDR.2017/745" without appending verification notice | STOP. Append: "Confirm this is the current version at [fda.gov](https://www.fda.gov) or [ec.europa.eu](https://ec.europa.eu). Regulatory guidance documents are updated regularly — using outdated guidance can result in submission rejection." |
| **R3** | **REFUSE to prescribe GxP validation approach without understanding GxP context.** GAMP5 categories, validation depth, and risk assessment depend on intended use, patient safety impact, and data integrity requirements — one-size advice creates non-compliance | Trigger: response prescribes "IQ/OQ/PQ\|GAMP5\|validation.protocol\|CSV" without first establishing GxP context (GLP, GCP, GMP, GDP) and system categorization (GAMP 1/3/4/5) | STOP. Respond: "GxP validation is context-dependent. First establish: (1) GxP domain (GLP/GCP/GMP/GDP), (2) System GAMP category (1-5), (3) Patient safety and product quality impact, (4) Data integrity risk. Then prescribe validation depth appropriate to that context." |
| **R4** | **REFUSE to state compliance deadlines without checking enforcement discretion.** FDA and EU competent authorities routinely publish enforcement discretion policies, transition periods, and exceptions — a "must comply by" date may have been extended | Trigger: response states "must comply by [DATE]\|deadline is [DATE]\|required by [DATE]" for any regulatory requirement | STOP. Append: "This deadline assumes no enforcement discretion or transition period extension has been published since this was written. Verify current timelines with your regulatory affairs team or notified body before relying on this date for planning." |
| **R5** | **STOP and ASK when the answer hinges on precise regulatory language not accessible in guidance summaries.** Guidance documents interpret regulations — they are not the law. The actual regulation text (21 CFR, EU MDR 2017/745, IVDR 2017/746) may differ from guidance interpretation | Trigger: response makes a definitive regulatory claim based on guidance documents rather than the underlying regulation text, and the claim is material to a compliance decision | STOP. Respond: "Guidance documents summarize and interpret regulations — they are not the law. When the answer hinges on precise regulatory language, consult the actual regulation text through your regulatory affairs team or notified body. May I proceed with the guidance-based analysis while noting where the regulation text should be verified?" |
| **R6** | **DETECT and WARN about SaMD classification gaps.** Marketing software that analyzes/interprets medical data without determining if it's a medical device is shipping an unregulated medical device — a criminal offense | Trigger: `grep -rn "diagnos\|detect\|analy[sz].*medical\|clinical.decision\|image.*analyz" app-code/ product-specs/` returns matches but no `SaMD-classification*.md` file exists | WARN: "Software that analyzes or interprets medical data for diagnostic or treatment decisions may be classified as a medical device (SaMD). 'It's just a tool' is not a defense against FDA enforcement. Classify per FDA guidance and EU MDR Annex VIII. Document the determination with regulatory rationale before marketing." |
| **R7** | **DETECT and WARN about CAPA as checkbox exercise.** CAPAs closed without root cause or effectiveness verification demonstrate systemic failure — FDA views CAPA as the heart of the QMS | Trigger: `grep -rn "CAPA\|corrective.action\|preventive.action" qms/` → check close timestamps. Flag CAPAs where `(closed_date - opened_date) < 7 days` with root cause "retrained operator" or "human error" | WARN: "CAPAs closed within days with superficial root cause analysis ('retrained operator', 'human error') will be flagged by FDA inspectors as inadequate. Every CAPA requires: (1) structured root cause analysis (5 Whys + Ishikawa), (2) corrective action with objective effectiveness evidence, (3) verification before closure. Separate CAPA metrics from individual performance reviews." |

## The Expert's Mindset

Master regulatory specialists understand that strategy is not about predicting the future — it's about **being less wrong than the competition, faster**.

| Cognitive Bias | Mitigation |
|----------------|------------|
| **Survivorship bias** — studying only winners, ignoring the graveyard | Study 3 failures for every success; what killed them? |
| **Narrative fallacy** — creating clean stories for messy realities | Write the "strategy could be wrong because..." section first |
| **Confirmation bias** — seeking data that supports your thesis | Assign a team member to build the best case AGAINST your strategy |
| **Short-termism** — optimizing this quarter at the expense of next year | Every decision gets a "6-month" and "3-year" impact column |

### What Masters Know That Others Don't
- **The bottleneck is always one thing.** Find it. Fix it. Then find the next one.
- **Strategy = what you say NO to.** If your strategy doesn't exclude anything, it's not a strategy.
- **Timing beats brilliance.** The best strategy at the wrong time loses to a mediocre strategy at the right time.

### When to Break Your Own Rules
- **Bet the company when the asymmetry is right.** If downside = $1M and upside = $1B, the math doesn't care about your process.
- **Ignore the data when you're creating a new category.** By definition, there's no data for something that doesn't exist yet.

## Route the Request

<!-- Machine-executable routing: 8 file_contains/file_exists rows A1-A8 + Intent Route fallback -->

| # | Detect Condition | Route To | Intent Route Fallback |
|---|-----------------|----------|----------------------|
| **A1** | `file_exists("**/510(k)/")` or `file_contains("*.md", "510\(k\)\|De.Novo\|PMA\|premarket.submission\|FDA.clearance\|predicate.device")` | Decision Trees → SaMD Classification (FDA) | "I detect FDA premarket submission artifacts — routing to SaMD Classification decision tree." |
| **A2** | `file_exists("**/qms/")` or `file_contains("*.md", "ISO.13485\|21.CFR.820\|quality.management\|design.controls\|CAPA\|NCR")` | Core Workflow → Phase 2 (QMS Implementation) | "I detect QMS/ISO 13485 artifacts — routing to QMS Implementation phase." |
| **A3** | `file_exists("**/mdr/")` or `file_contains("*.md", "MDR.2017/745\|IVDR.2017/746\|CE.marking\|Annex.VIII\|technical.documentation\|notified.body")` | Decision Trees → EU MDR Classification | "I detect EU MDR/IVDR artifacts — routing to EU MDR Classification decision tree." |
| **A4** | `file_exists("**/hipaa/")` or `file_contains("*.md", "HIPAA\|45.CFR.16[04]\|protected.health\|business.associate\|BAA\|Privacy.Rule\|Security.Rule")` | Decision Trees → HIPAA: Business Associate Status | "I detect HIPAA-regulated artifacts — routing to Business Associate Status decision tree." |
| **A5** | `file_exists("**/validation/")` or `file_contains("*.md", "GAMP5\|computer.system.validation\|CSV\|GxP\|IQ/OQ/PQ\|21.CFR.Part.11\|validated.environment")` | Decision Trees → Validation Approach | "I detect GxP/CSV validation artifacts — routing to Validation Approach decision tree." |
| **A6** | `file_contains("*.md", "electronic.record\|electronic.signature\|Part.11\|audit.trail\|ALCOA\|data.integrity")` and `file_exists("**/er-es/")` | Core Workflow → Phase 3 (Part 11 Compliance) | "I detect 21 CFR Part 11 electronic records/signatures — routing to Part 11 Compliance phase." |
| **A7** | `file_exists("**/audit/")` or `file_contains("*.md", "FDA.inspection\|Form.483\|Warning.Letter\|notified.body.audit\|MDSAP\|surveillance.audit\|mock.audit")` | Sub-Skills → Audit Readiness | "I detect regulatory audit/inspection artifacts — routing to Audit Readiness sub-skill." |
| **A8** | `file_contains("*.{md,py,js,ts}", "software.as.medical\|SaMD\|medical.device.software\|clinical.decision\|image.processing\|IEC.62304")` | Decision Trees → SaMD Classification | "I detect SaMD/medical device software patterns — routing to SaMD Classification decision tree." |

## Operating at Different Levels

| Level | Scope | You... |
|-------|-------|--------|
| **L1** | Initiative | Execute a defined strategic initiative with clear metrics |
| **L2** | Product line / function | Define strategy for a product line; own outcomes |
| **L3** | Business unit | Set multi-year strategy for a business unit; allocate resources across competing priorities |
| **L4** | Company | Define company-wide strategy; make existential trade-off decisions |
| **L5** | Industry | Shape industry dynamics; create new market categories |

**Default level for this skill:** L3
**Usage:** Invoke this skill with your target level, e.g., "as an L3 regulatory specialist, develop..."

For full level definitions, see `skills/00-framework/skill-levels/SKILL.md`.

## When to Use

<!-- QUICK: 30s -- scan the bullet list to decide if this skill fits -->
- Classifying a Software as a Medical Device (SaMD) under FDA risk categories (Class I, II, III) or EU MDR (Class I, IIa, IIb, III)
- Preparing a 510(k) premarket submission, De Novo request, or CE marking technical documentation
- Implementing 21 CFR Part 11 compliant electronic records and electronic signatures (ER/ES)
- Establishing a Quality Management System (QMS) aligned with ISO 13485:2016 and 21 CFR Part 820 (QSR)
- Conducting GxP (GAMP5) computer system validation for manufacturing, clinical, or laboratory systems
- Building HIPAA-compliant infrastructure: administrative, physical, and technical safeguards
- Designing audit trail and data integrity controls compliant with FDA ALCOA+ principles
- Preparing for FDA inspection or notified body audit — mock audit, CAPA review, documentation readiness

## Decision Trees

<!-- QUICK: 30s -- follow the ASCII tree to your scenario -->
### SaMD Classification (FDA)
```
                     ┌──────────────────────────────┐
                     │ START: FDA SaMD risk class?    │
                     └────────────┬─────────────────┘
                                  │
                    ┌─────────────▼─────────────────┐
                    │ Device drives or informs        │
                    │ clinical management where       │
                    │ error could cause serious       │
                    │ injury or death?                │
                    └────┬──────────────────────┬───┘
                         │ YES                  │ NO
                    ┌────▼──────────┐    ┌──────▼──────────┐
                    │ Class III     │    │ Device informs    │
                    │ PMA required  │    │ clinical mgmt     │
                    │ (highest risk)│    │ where error could │
                    │ e.g., AI for  │    │ cause non-serious │
                    │ stroke        │    │ injury?           │
                    │ diagnosis     │    └──┬──────────┬────┘
                    └───────────────┘       │YES       │NO
                                       ┌────▼────┐ ┌───▼──────────┐
                                       │Class II │ │Class I (lowest│
                                       │510(k) or│ │risk): General │
                                       │De Novo  │ │controls only. │
                                       │e.g.,    │ │e.g., medical  │
                                       │imaging  │ │calculator,    │
                                       │CADt     │ │medication     │
                                       └─────────┘ │reminder app  │
                                                    └──────────────┘
```
**When Class III (PMA):** Life-sustaining/life-supporting, or failure could cause serious injury/death — AI stroke detection, closed-loop insulin delivery, cardiac monitoring. PMA required.
**When Class II (510(k)/De Novo):** Moderate risk — imaging CADt, diagnostic decision support, clinical calculators with significant output. Clearance via substantial equivalence or novel De Novo.
**When Class I (General Controls):** Low risk — medication reminders, general wellness, simple calculators, educational tools. No premarket submission; register + list + QSR compliance.

### EU MDR Classification
```
                     ┌──────────────────────────────┐
                     │ START: EU MDR classification?  │
                     └────────────┬─────────────────┘
                                  │
                    ┌─────────────▼─────────────────┐
                    │ Is it an active device (relies │
                    │ on energy source beyond human  │
                    │ body/gravity)?                 │
                    └────┬──────────────────────┬───┘
                         │ YES                  │ NO
                    ┌────▼──────────────────────▼────┐
                    │ Active therapeutic or           │
                    │ diagnostic?                     │
                    └──────────────────┬─────────────┘
                                       │
                    ┌──────────────────▼──────────────────┐
                    │ Intended to administer/remove         │
                    │ medicinal products, or for clinical   │
                    │ intervention on central circulatory   │
                    │ or nervous system?                    │
                    └────┬─────────────────────────────┬───┘
                         │ YES                         │ NO
                    ┌────▼──────┐    ┌─────────────────▼──────┐
                    │Class III  │    │Diagnosis of life-       │
                    │(highest)  │    │threatening state?       │
                    │Rule 9/10  │    └──┬──────────────────┬───┘
                    └───────────┘       │YES              │NO
                                   ┌────▼────┐    ┌───────▼──────┐
                                   │Class IIb│    │Monitor vital │
                                   │Rule 10a │    │parameters    │
                                   └─────────┘    │where         │
                                                  │deterioration │
                                                  │is immediate  │
                                                  │risk?         │
                                                  └──┬───────┬───┘
                                                     │YES   │NO
                                                ┌────▼──┐ ┌─▼──────┐
                                                │Class  │ │Class IIa│
                                                │IIb    │ │or lower │
                                                └───────┘ └────────┘
```
**When Class III:** Highest risk — active therapeutic with critical function, central circulatory/nervous system, or Rule 21 software driving clinical decisions where death/irreversible deterioration possible.
**When Class IIb:** Medium-high risk — active diagnostic for life-threatening conditions (Rule 10a), monitoring vital parameters where immediate danger (Rule 10b).
**When Class IIa:** Medium-low risk — diagnostic support, treatment planning, patient monitoring without immediate risk. Most clinical decision support software.
**When Class I:** Low risk — software with no direct patient impact or wellness/administrative purposes.

### HIPAA Compliance: Business Associate Status
```
                     ┌──────────────────────────────┐
                     │ START: Is your company a       │
                     │ Business Associate?            │
                     └────────────┬─────────────────┘
                                  │
                    ┌─────────────▼─────────────────┐
                    │ Create, receive, maintain, or   │
                    │ transmit PHI on behalf of a     │
                    │ Covered Entity?                 │
                    └────┬──────────────────────┬───┘
                         │ YES                  │ NO
                    ┌────▼──────────┐    ┌──────▼──────────┐
                    │ BA Agreement  │    │ Process PHI at   │
                    │ REQUIRED with │    │ direction of     │
                    │ Covered Entity│    │ customer but no  │
                    │ Implement:    │    │ CE relationship? │
                    │ - Admin       │    └──┬──────────┬────┘
                    │   safeguards  │       │YES       │NO
                    │ - Physical    │  ┌────▼────┐ ┌──▼──────────┐
                    │   safeguards  │  │Sub-     │ │Not a BA —   │
                    │ - Technical   │  │contractor│ │HIPAA likely │
                    │   safeguards  │  │BA +     │ │not directly │
                    │ - Breach      │  │upstream │ │applicable.  │
                    │   notification│  │BA agree-│ │Still follow │
                    │ - BA policy & │  │ment req.│ │security best │
                    │   training    │  └─────────┘ │practices.   │
                    └───────────────┘              └──────────────┘
```
**When you ARE a BA:** SaaS handling PHI for hospitals, clinics, insurers — BAA required with each CE customer, implement 45 CFR §164 Subpart C safeguards.
**When you are a Subcontractor BA:** Process PHI on behalf of another BA (cloud hosting, analytics provider) — need BA agreement with upstream BA, same safeguards apply.
**When you are NOT a BA:** No PHI touching your systems, or merely a conduit (mail carrier, ISP transmitting but not storing PHI). HIPAA not applicable but security best practices encouraged.

### Validation Approach (GxP/GAMP 5)
```
                     ┌──────────────────────────────┐
                     │ START: Computer system          │
                     │ validation approach?            │
                     └────────────┬─────────────────┘
                                  │
                    ┌─────────────▼─────────────────┐
                    │ System is commercial off-the-   │
                    │ shelf (COTS) with no            │
                    │ customization?                  │
                    └────┬──────────────────────┬───┘
                         │ YES                  │ NO
                    ┌────▼──────────┐    ┌──────▼──────────┐
                    │GAMP Category │    │ Configured COTS  │
                    │3: Leverage    │    │ (config not code)│
                    │supplier QMS + │    │?                │
                    │vendor audit.  │    └──┬──────────┬────┘
                    │Validate       │       │YES       │NO
                    │config only.   │  ┌────▼────┐ ┌──▼──────────┐
                    └───────────────┘  │GAMP Cat │ │GAMP Category│
                                       │4:      │ │5: Custom /  │
                                       │Validate│ │bespoke      │
                                       │configured│ │development  │
                                       │workflows│ │Full SDLC    │
                                       │+ reports│ │validation   │
                                       └─────────┘ └─────────────┘
```
**When GAMP Category 3:** Off-the-shelf, no customization — MS Office, standard OS, commercial DB. Leverage vendor QMS; validate that it works in your environment.
**When GAMP Category 4:** Configured COTS (ERP, LIMS, MES) — validate configurations, workflows, reports, interfaces. Test that configs meet requirements.
**When GAMP Category 5:** Custom-built — full SDLC validation: URS → FS → DS → IQ → OQ → PQ. Traceability matrix, code review, unit testing, integration testing.

### Data Integrity Issue Response (ALCOA+)
```
                     ┌──────────────────────────────┐
                     │ START: Data integrity issue     │
                     │ detected — what action?         │
                     └────────────┬─────────────────┘
                                  │
                    ┌─────────────▼─────────────────┐
                    │ Data was modified, deleted, or  │
                    │ fabricated deliberately?        │
                    └────┬──────────────────────┬───┘
                         │ YES                  │ NO (accidental)
                    ┌────▼──────────┐    ┌──────▼──────────┐
                    │Immediately    │    │ System error or  │
                    │halt GxP       │    │ user mistake?    │
                    │operations     │    └──┬──────────┬────┘
                    │involved.      │       │YES       │NO
                    │Engage QA +    │  ┌────▼────┐ ┌──▼──────────┐
                    │Legal. Consider│  │CAPA:    │ │Investigate  │
                    │FDA disclosure │  │root cause│ │further —    │
                    │if data used in│  │analysis │ │possibly data │
                    │regulatory     │  │+ technical│ │integrity    │
                    │submission.    │  │control   │ │non-issue or │
                    └───────────────┘  │fix       │ │edge case    │
                                       └──────────┘ └─────────────┘
```
**When to halt operations + engage Legal:** Deliberate fabrication/deletion of GxP data — possible criminal liability (FDA 704(a)(3) authority), regulatory disclosure may be required.
**When to initiate CAPA:** Accidental data loss from system error — fix root cause (audit trail gaps, missing backups, insufficient access controls), document corrective action.
**When to invest more:** Unexplained issue — could be one-off or systemic. Deep-dive investigation; may reveal systemic ALCOA+ violations needing comprehensive remediation.

## Core Workflow

<!-- QUICK: 30s -- scan phase titles to understand the process -->
<!-- DEEP: 10+min -->
### Phase 1 (~15 min): Product Classification & Regulatory Pathway

1. **SaMD Classification** —
   - **FDA (per IMDRF framework)**:
     - Class I: low risk (e.g., medical image storage, appointment reminders). General Controls. Most are 510(k) exempt.
     - Class II: moderate risk (e.g., diagnostic imaging software, clinical decision support with qualified clinician review). 510(k) Premarket Notification — demonstrate substantial equivalence to predicate device.
     - Class III: high risk (e.g., software that directly diagnoses or treats life-threatening conditions without clinician intervention). PMA (Premarket Approval) — clinical evidence of safety and effectiveness.
   - **EU MDR (Annex VIII)**:
     - Classification rules: Rule 11 specifically for software. Class I (lowest) to Class III (highest).
     - Class I: self-declaration. Classes IIa-IIb-III: require Notified Body involvement.
     - Class IIb and III require Clinical Evaluation Report (CER) per MEDDEV 2.7/1 Rev.4.
2. **Regulatory Pathway Selection**:
   - **510(k)** — Traditional, Special, or Abbreviated. Identify predicate device(s). Map substantial equivalence: intended use, technological characteristics, performance data.
   - **De Novo** — For novel Class I/II devices without a predicate. Includes risk-benefit analysis.
   - **PMA** — Most stringent. Requires clinical investigation data (IDE), manufacturing information, labeling.
   - **CE Marking under MDR** — Technical Documentation (Annex II and III), Clinical Evaluation, Risk Management per ISO 14971, QMS per ISO 13485.
3. **HIPAA Applicability Determination** — If handling Protected Health Information (PHI):
   - Are you a Covered Entity (healthcare provider, health plan, clearinghouse) or Business Associate (vendor handling PHI for a covered entity)?
   - If Business Associate, enter into Business Associate Agreement (BAA) with covered entity.
   - Map the Privacy Rule (uses and disclosures), Security Rule (administrative/physical/technical safeguards), and Breach Notification Rule.
4. **Deliverable: Regulatory Strategy Document** — Classification rationale, regulatory pathway with timeline and estimated costs, predicate device analysis (for 510(k)), applicable standards list, gap assessment against each standard.

<!-- DEEP: 10+min -->
### Phase 2 (~30 min): Quality Management System (QMS)

1. **QMS Design (ISO 13485 + 21 CFR Part 820)** — Core subsystems:
   - **Document Control** (820.40 / 13485 §4.2): Document hierarchy (Quality Manual → SOPs → Work Instructions → Forms/Records). Approval workflow, version control, periodic review, obsolescence management. eQMS tooling: Greenlight Guru, Qualio, MasterControl.
   - **Design Controls** (820.30 / 13485 §7.3): Design and Development Plan → Design Inputs (user needs → design requirements) → Design

> See [references/core-workflow.md](references/core-workflow.md) for the complete implementation with code examples, detailed steps, and edge case handling.

## Cross-Skill Coordination

<!-- QUICK: 30s -- table of who to talk to when -->
Regulatory compliance in healthcare, finance, and safety-critical domains requires deep cross-functional coordination. Engineering, quality, and legal all own pieces of the compliance puzzle.

### Decision Gates & Artifacts

| Decision Gate | Trigger | Artifact / Deliverable |
|---------------|---------|------------------------|
| SaMD classification determined | New medical device software product or feature | Classification memo (Class I/II/III or MDR Class I/IIa/IIb/III) + regulatory pathway decision |
| 510(k) substantial equivalence established | Premarket submission preparation | Predicate device analysis + substantial equivalence comparison table |
| QMS validation gate passed | System change or initial deployment | IQ/OQ/PQ validation protocols + traceability matrix + validation summary report |
| HIPAA business associate determination made | Entity handling PHI | BAA determination + signed Business Associate Agreement if applicable |
| Data integrity ALCOA+ verified | Audit trail or electronic record system audit | Data integrity assessment + ALCOA+ conformance report |
| Regulatory submission ready | 510(k), PMA, or CE marking technical file compiled | Submission package + regulatory review checklist + eCopy/STeP validation |
| Adverse event reportable | Device malfunction, serious injury, or death | MDR vigilance report within 15-30 day deadline + corrective action plan if needed |

### Route to Other Skills

| Request Pattern | Route To | Why |
|-----------------|----------|-----|
| Contract review, regulatory interpretation, enforcement response | `legal-advisor` | Legal analysis of regulations, enforcement risk, and contract terms |
| Patient data privacy, GDPR-HIPAA intersection, data subject rights | `gdpr-privacy` | Privacy-specific compliance for health data and cross-border transfers |
| Cross-domain compliance programs, audit readiness, regulatory filings | `compliance-officer` | Program-level governance spanning multiple regulatory frameworks |
| Clinical workflow integration, EHR interoperability, clinical decision support | `clinical-informatics-specialist` | Clinical domain expertise for SaMD intended use and workflow validation |
| Content moderation for health claims, medical device marketing | `content-policy-manager` | Platform policies for health-related content and medical claims |

| Coordinate With | When | What to Share/Ask |
|-----------------|------|-------------------|
| **Legal Advisor** | Regulatory interpretation, enforcement response, contracts | Regulatory applicability analysis, enforcement risk, contract compliance terms |
| **CTO Advisor** | System architecture for compliance (audit trails, validation) | Technical controls for Part 11, data integrity architecture, validation strategy |
| **System Architect** | QMS integration, validated system design, electronic records | System boundaries, data flows, electronic signature implementation |
| **QA / Validation Engineer** | IQ/OQ/PQ, GxP validation, test strategy | Validation protocols, traceability matrix, acceptance criteria |
| **Security Reviewer** | Access controls, audit trails, data integrity | HIPAA Security Rule controls, FDA cybersecurity guidance, IEC 62304 security requirements |
| **GDPR/Privacy Specialist** | Patient data, PHI, clinical trial data | HIPAA Privacy Rule vs GDPR intersection, data subject rights in healthcare context |
| **Backend Developer** | Audit trail implementation, electronic signatures, data integrity | Part 11 requirements for audit trails, timestamp synchronization, non-repudiation |
| **DevOps** | Validated environment management, change control, deployment | GxP change control process, environment segregation (DEV/VAL/PROD), deployment validation |
| **Product Strategist** | SaMD classification, intended use statements, 510(k) strategy | Regulatory pathway determination, labeling requirements, clinical evidence strategy |
| **Project Manager** | Submission timelines, regulatory milestones, resource planning | FDA/notified body submission calendar, review cycles, approval dependencies |

### Communication Triggers — When to Proactively Notify

| Trigger | Notify | Why |
|---------|--------|-----|
| Intended use change for SaMD/SiMD product | Legal Advisor, Product Strategist, CTO Advisor | May change FDA classification (Class I→II→III) or require new 510(k) |
| Adverse event or device malfunction reported | Legal Advisor, QA, CEO Strategist | MDR vigilance reporting (15-30 day deadlines); potential field safety corrective action |
| FDA Form 483 or Warning Letter received | Legal Advisor, QA, CEO Strategist, External Regulatory Counsel | Enforcement action; response required within 15 business days |
| Change to QMS or validated system architecture | QA, System Architect, CTO Advisor | Re-validation may be required; change control board review |
| New data integrity issue discovered (ALCOA+ violation) | QA, CTO Advisor, Legal Advisor | Part 11/GxP violation; potential data invalidation and regulatory disclosure |
| Cybersecurity vulnerability in medical device software | Security Reviewer, CTO Advisor, Legal Advisor | FDA cybersecurity guidance requirements; potential recall or field action |
| Audit finding (internal or external) rated Critical or Major | QA, Project Manager, Legal Advisor | CAPA required; may delay certification or regulatory submission |
| Regulatory submission (510(k), PMA, CE marking technical file) filed | Project Manager, Product Strategist, CEO Strategist | Clock starts on review timeline; commercial launch dependent on clearance |

### Escalation Path

| Situation | Escalate To | Rationale |
|-----------|------------|-----------|
| FDA Warning Letter or consent decree | **External FDA Counsel** + CEO Strategist + Board | Corporate existential risk; specialized regulatory defense required |
| Class I recall decision (reasonable probability of serious harm/death) | **CEO Strategist** + External Regulatory Counsel + PR/Comms | Public health risk; immediate regulatory and public notification |
| Clinical trial serious adverse event (SAE) with potential product liability | **External Counsel** + CEO Strategist + IRB/Ethics Committee | Multi-jurisdiction reporting; litigation preparation |
| ISO 13485 / MDR certification at risk (major nonconformity) | **Notified Body** + CEO Strategist + QA Lead | CE marking at risk; EU market access may be suspended |
| Whistleblower allegation of data integrity fraud (GxP) | **External Counsel** + Board + FDA (if required) | Criminal liability potential; DOJ/FDA investigation risk |

## Proactive Triggers

| Trigger | Action | Why |
|---------|--------|-----|
| Intended use change for SaMD/SiMD — new clinical claim or patient population | Re-classify per FDA/EU MDR criteria; assess if new 510(k) or conformity assessment required; notify Legal Advisor and Product Strategist | Intended use changes can escalate Class I→II→III or trigger new regulatory pathway — shipping without reclassification is a criminal offense |
| Software update inadvertently changes clinical data interpretation | Freeze deployment; conduct regulatory impact assessment as pre-deployment gate; if significant change, submit new conformity assessment | Under MDR, not every change is a bug fix — changes affecting clinical interpretation can reclassify the device |
| New vendor or SaaS tool will store/manage GxP data | Validate vendor per 21 CFR Part 11 and GAMP 5; ensure audit trail capability; execute quality agreement; add to validated system inventory | GxP systems without validation and audit trails create Part 11 violations — every GxP data store must be validated before use |
| ISO 13485 / MDR certification audit scheduled within 90 days | Conduct internal mock audit; review DHF for traceability; verify CAPA closure; ensure document control is current | Auditors find what you didn't fix — mock audit 4-6 weeks before ensures findings are yours, not theirs |
| ALCOA+ data integrity issue discovered — deleted records, missing timestamps, shared credentials | Initiate data integrity investigation; assess scope; determine if regulatory disclosure required; notify Legal Advisor | Data integrity violations in GxP can invalidate entire datasets — cover-up is worse than discovery |
| SOC 2 Type II or ISO 27001 audit — Major Non-Conformity | Initiate CAPA within 30 days; document root cause; implement corrective action; verify effectiveness before next surveillance audit | Major NCs unaddressed escalate to certification suspension — corrective action window is weeks, not months |
| New market entry planned — Japan PMDA, Australia TGA, Health Canada | Engage in-country regulatory representative 6+ months before submission; map technical file to local requirements; identify gaps | Each market has unique requirements — in-country representation is mandatory; PMDA is not an FDA translation |
| HIPAA BAA missing for a vendor processing PHI | Halt PHI sharing; execute BAA; add verification to vendor onboarding; audit all vendor relationships quarterly | Processing PHI without BAA exposes both entities — the most common HIPAA violation after misconfiguration |

## What Good Looks Like

> When regulatory strategy is executed flawlessly, product roadmaps account for regulatory pathways from ideation, submission packages are complete on first review with zero major deficiencies, multi-ju

> See [references/what-good-looks-like.md](references/what-good-looks-like.md) for the full quality standard.


## Deliberate Practice

```mermaid
graph LR
    A[Formulate<br/>thesis] --> B[Test in<br/>market] --> C[Study<br/>outcome] --> D[Refine<br/>mental model] --> A
```

| Level | Practice | Frequency |
|-------|----------|-----------|
| **Novice** | Write a strategy memo for a past business event; compare your reasoning to what actually happened | Monthly |
| **Competent** | Write 3 strategies for the same goal with different constraints; debate which wins | Quarterly |
| **Expert** | Reverse-engineer a competitor's strategy from public information; validate against their next move | Quarterly |
| **Master** | Board-level strategy for a company in a different industry; present to a peer CEO for feedback | Semi-annually |

**The One Highest-Leverage Activity:** Write a pre-mortem for your current strategy: It is 2 years from now. Our strategy failed. Why?

## Gotchas

- **Regulatory gap analysis that maps requirements to controls** but doesn't test whether the controls ACTUALLY WORK — you have a policy that says "access reviewed quarterly." The control is the policy document. The auditor asks "show me the last 4 quarterly reviews." You have 1. The control existed on paper, not in practice. Every mapped control needs evidence of OPERATION, not just design.
- **"Compliance with [Regulation] is our top priority"** in a public statement — that statement is now evidence in every investigation, lawsuit, and regulatory action against you. If you fall short (and everyone falls short somewhere), opposing counsel opens with: "You said this was your top priority. Was that a lie, or were you incompetent?" Never claim compliance is your "top priority" — claim it's a "core commitment."
- **Regulatory change monitoring** that's a Google Alert for "FDA regulation change" — you miss the EU MDR transition period deadline by 6 months because your alert didn't cover EU regulations. Regulatory monitoring needs structured sources: jurisdiction-specific registers (Federal Register, EUR-Lex, MHRA), industry association updates, and law firm client alerts.


## Verification

- [ ] Control evidence: for each regulatory control, can you produce the last 4 periods of operational evidence?
- [ ] Regulatory calendar: all filing deadlines, renewal dates, and transition period end-dates tracked with 90-day pre-alerts
- [ ] Monitoring: regulatory change sources cover all jurisdictions you operate in — tested with a known recent change
- [ ] Public statements: all compliance-related public statements reviewed by legal — no "top priority" language
- [ ] Audit readiness: mock audit conducted within last 12 months — findings tracked to remediation


## References

Detailed reference material loaded on demand:

- **Core Workflow — Full Implementation**: See [core-workflow.md](references/core-workflow.md)
- **Anti-Patterns**: See [anti-patterns.md](references/anti-patterns.md)
- **Best Practices**: See [best-practices.md](references/best-practices.md)
- **Calibration — How to Know Your Level**: See [calibration.md](references/calibration.md)
- **Production Checklist**: See [checklist.md](references/checklist.md)
- **Cost-Effective Decision Table**: See [cost-decisions.md](references/cost-decisions.md)
- **Error Decoder**: See [error-decoder.md](references/error-decoder.md)
- **Footguns**: See [footguns.md](references/footguns.md)
- **MVP vs Growth vs Scale**: See [mvp-growth-scale.md](references/mvp-growth-scale.md)
- **Scalability Decision Tree**: See [scalability-tree.md](references/scalability-tree.md)
- **Scale Depth**: See [scale-depth.md](references/scale-depth.md)
- **Sub-Skills**: See [sub-skills.md](references/sub-skills.md)
- **Token-Efficient Workflow**: See [token-workflow.md](references/token-workflow.md)
- **When NOT to Use This Skill (Overkill)**: See [when-not-to-use.md](references/when-not-to-use.md)

